Similar articles

• Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.

  Garcia-Montojo M, Dominguez-Mozo MI, de las Heras V, Bartolome M, Garcia-Martinez A, Arroyo R, Alvarez-Lafuente R. Garcia-Montojo M, et al. Eur J Neurol. 2010 Mar;17(3):470-8. doi: 10.1111/j.1468-1331.2009.02890.x. Epub 2009 Dec 27. Eur J Neurol. 2010. PMID: 20050906
• Matrix metalloproteinases biomarkers in multiple sclerosis.

  Rosenberg GA. Rosenberg GA. Lancet. 2005 Apr 9-15;365(9467):1291-3. doi: 10.1016/S0140-6736(05)61008-2. Lancet. 2005. PMID: 15823367 No abstract available.
• Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury?

  Bever CT Jr, Rosenberg GA. Bever CT Jr, et al. Neurology. 1999 Oct 22;53(7):1380-1. doi: 10.1212/wnl.53.7.1380. Neurology. 1999. PMID: 10534237 Review. No abstract available.
• Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis.

  Yılmaz Ü, Gücüyener K, Atak A, Aral A, Gürkaş E, Demir E, Serdaroğlu A. Yılmaz Ü, et al. Pediatr Neurol. 2012 Sep;47(3):171-6. doi: 10.1016/j.pediatrneurol.2012.05.027. Pediatr Neurol. 2012. PMID: 22883281
• Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.

  Hegen H, Auer M, Deisenhammer F. Hegen H, et al. Expert Opin Drug Metab Toxicol. 2015;11(12):1803-19. doi: 10.1517/17425255.2015.1094055. Epub 2015 Sep 30. Expert Opin Drug Metab Toxicol. 2015. PMID: 26419922 Review.